Search Results
Your search for all items matches 34784 pages
Showing 17901 - 17950WHO Names St. Jude Its First Collaborating Center for Childhood Cancer
THE WORLD HEALTH ORGANIZATION (WHO) has designated St. Jude Children’s Research Hospital as the first WHO Collaborating Center for Childhood Cancer. With this collaboration, both organizations aim to expand efforts to develop strategies to strengthen the global resources, organization, and planning ...
Researchers at Baylor Awarded Multiple Grants to Study Treatment Resistance in Breast Cancer
TO BETTER UNDERSTAND the causes of resistance to treatment in estrogen receptor–positive breast cancer, the Department of Defense has awarded researchers at Baylor College of Medicine multiple grants to study gene anomalies in estrogen receptor–positive breast cancer that are associated with...
Disparities Found in Lung Cancer Care, Survival in United States vs England
DESPITE STEADY declines in death rates in recent years, lung cancer remains the leading cause of cancer deaths in wealthy countries. In a study published by Anita Andreano, MD, of the University of Milan-Ciocco, and colleagues in the Journal of Thoracic Oncology,1 Yale researchers collaborated with ...
Actively Recruiting Clinical Trials Focused on Pancreatic Cancer
THE INFORMATION contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on pancreatic cancer. These studies are investigating radiotherapy; cancer vaccines; combination treatments; novel cell therapies; response prediction; and more. All of the studies ...
Handheld Device for Detecting Heart Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer
Cardiovascular complications, such as anthracycline-related heart failure, are a leading cause of morbidity and mortality in survivors of childhood cancer, often developing at a time when these survivors are least engaged in long-term survivorship care, prompting the need for new paradigms in...
FDA Grants Priority Review to Expanded Use of Gardasil 9 in Women and Men Aged 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases
On June 13, the U.S. Food and Drug Administration (FDA) accepted for review a new supplemental biologics license application (sBLA) for recombinant human papillomavirus (HPV) 9-valent vaccine (Gardasil 9). The application is seeking approval for an expanded age...
Statement From FDA Commissioner on Agency Efforts to Advance the Patient Voice in Medical Product Development and Regulatory Decision-Making
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, recently issued the following statement: Over the past decade, advances in our understanding of the basic biology of serious and life-threatening diseases has led to the development and FDA approval of targeted treatments for ...
AMA Plans Advocacy Outreach to Expand Colorectal Screening
Building on the efficacy of colorectal cancer screening, the American Medical Association (AMA) endorsed a plan at its Annual Meeting to work with physicians and payers to make the screening more available and affordable. Challenges with insurance coverage remain a barrier to colorectal cancer...
Ibrutinib in Relapsed or Refractory Follicular Lymphoma
In the phase II DAWN study reported in the Journal of Clinical Oncology, Gopal et al found that ibrutinib (Imbruvica) produced a response in a minority of patients with relapsed or refractory follicular lymphoma. Study Details In the study, 110 patients with ≥ 2 prior lines of treatment...
Suboptimal Use of Initial Chemotherapy in Newly Diagnosed AML
In a study of National Cancer Database data reported in Blood Advances, Bhatt et al found that 25% of patients with newly diagnosed acute myeloid leukemia (AML) did not receive initial chemotherapy, despite evidence that chemotherapy is associated with a survival benefit and improvement in symptoms ...
Green Tea
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on the potential health benefits ...
Harvard Business School Launches Initiative to Accelerate Precision Medicine in Oncology
THE HARVARD BUSINESS School Kraft Precision Medicine Accelerator, a multidisciplinary initiative with aims to advance precision medicine, focuses on four workstreams: Direct to Patient, Data & Analytics, Clinical Trials, as well as Venture and Investment. It was recently announced that under...
From Italy to Boston, A Love of Molecular Diagnostics Shapes a Career for Valentina Nardi, MD
Valentina Nardi, MD, is a staff pathologist at Massachusetts General Hospital, and her current clinical work includes implementing molecular assays for hematologic malignancies at the Center for Integrated Diagnostics. “I was born in Rome, but I did my high school and college education in Genoa. I ...
Richard D. Schulick, MD, MBA, Named Director of University of Colorado Cancer Center
RICHARD D. SCHULICK, MD, MBA, a cancer surgeon and administrative leader, has been named Director of the University of Colorado Cancer Center, a consortium of three universities and three academic teaching hospitals. The University of Colorado Cancer Center is the hub of cancer research in the...
Steven A. Rosenberg, MD, PhD, Receives American College of Surgeons Jacobson Innovation Award
THE 2018 JACOBSON INNOVATION AWARD of the American College of Surgeons was recently presented to Steven A. Rosenberg, MD, PhD, Chief of the Surgery Branch at the National Cancer Institute (NCI) as well as Professor of Surgery at the Uniformed Services University of Health Sciences and at the...
How Learning What’s on Your Patient’s Bucket List May Improve Care
It may sound too good to be true, but asking patients a simple question about what is on their bucket list can actually spark a dialogue about how best to make their cancer care and survivorship fit into their life plans, as well as be an effective way to identify their end-of-life care goals,...
ESMO Prioritizes Cancer Care at 71st World Health Assembly
AT THE 71ST World Health Assembly in Geneva, the European Society for Medical Oncology (ESMO) delivered two statements positioning cancer as a priority on the global agenda of the World Health Organization (WHO). Presenting its recommendations for action to the international community, ESMO...
Voluntarily Stopping Eating and Drinking Is Legal—and Ethical—for Terminally Ill Patients Looking to Hasten Death
Terminally ill patients with cancer will sometimes ask their clinicians for help with assisted or hastened death.1 Although palliative care and hospice care can usually address the concerns of most patients, some have physical or existential suffering that is refractory to comfort and supportive...
Meet Federal Reporting Requirements With QOPI® Reporting Registry
The QOPI® Reporting Registry, a Qualified Clinical Data Registry (QCDR) brought to you by ASCO and the American Society for Radiation Oncology (ASTRO), is your one-stop shop for 2018 Centers for Medicare and Medicaid Services (CMS) Merit-based Incentive Payment System (MIPS) reporting. The new...
Patients With AML Have Reduced Risk of Early Mortality at NCI-Designated Cancer Centers
RESEARCHERS AT the University of California (UC), Davis, have shown that patients with acute myeloid leukemia (AML) who received their care at a National Cancer Institute (NCI) cancer center in California had a dramatically reduced risk of early mortality. Using data from the California Cancer...
Leave a Legacy of Hope
By including a planned gift to ASCO’s Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for patients with cancer years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and: ...
Register Today for the ASCO Research Community Forum 2018 Annual Meeting
This year’s ASCO Research Community Forum (RCF) 2018 Annual Meeting will not be one to miss! Though still a few months away, I am thrilled to share the work that is already underway to bring the research community together for 2 days of learning and collaboration. During my term as Chair of the...
Updated: Cancer.Net Mobile App for Your Patients
Tell your patients about Cancer.Net’s award-winning mobile app! Recently updated, the newest version features several performance upgrades to improve the user experience, plus all the same great features offered before, including filtering capabilities, calendar integration, and native Spanish...
Resilience While Caring for Seriously Ill Patients: Skills and Strategies to Prevent Burnout
A career in oncology can be extremely rewarding. Fast-paced advances in research and treatment, exciting changes in the practice environment, and the opportunity to build strong relationships with and provide critical support to patients can be incredibly professionally satisfying—but they can...
Expert Point of View: Julie Margenthaler, MD, FACS
JULIE MARGENTHALER, MD, FACS, a breast surgeon at Washington University School of Medicine and American Society of Breast Surgeons Communications Committee Chair, highlighted the importance of exploring clinical endpoints outside of a survival advantage. “While numerous studies have shown the...
Regular Mammograms Linked to Less Aggressive Treatment in Patients With Breast Cancer
A STUDY evaluating the impact of breast cancer screening has shown that the benefits of regular mammograms extend well beyond reduced mortality. According to data presented at the American Society of Breast Surgeons (ASBrS) 2018 Annual Meeting, women with breast cancer who underwent regular...
AJCC Breast Cancer Staging System More Clinically Relevant
THE RECENTLY issued 8th revision to the American Joint Committee on Cancer (AJCC) Breast Cancer Staging System incorporates tumor biology and prognostic stage groups and thus has become more accurate and clinically relevant, according to two speakers at the 2018 Miami Breast Cancer Conference.1,2...
Folakemi Odedina, PhD, Awarded Fellowship for Oncology Clinical Trials in Africa
FOLAKEMI ODEDINA, PhD, Professor of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy, has been awarded a 2018 Carnegie African Diaspora Fellowship to help expand oncology clinical trials in Africa. Dr. Odedina will travel to South Africa to collaborate...
Dan Theodorescu, MD, PhD, Appointed Director of Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai
DAN THEODORESCU, MD, PhD, has been named Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, a position he will assume starting July 1, 2018. Dr. Theodorescu, a translational cancer researcher and expert in bladder cancer, will direct the oncology enterprise at...
Researchers Can Access Wide Array of ASCO Data Through CENTRA
Researchers can access a wide array of ASCO data through the Society’s Center for Research and Analytics (CENTRA). A detailed list of the data, along with samples of each data set, can be found on CENTRA’s updated data library page. ASCO maintains an expansive repository of information that...
Be Counted—Complete the 2018 ASCO Practice Census Today
ASCO invites you to participate in the 2018 ASCO Practice Census. Just as you monitor the health of your patients, ASCO regularly gathers information on the oncology practice environment, and we need your help to do so. The ASCO Practice Census is an annual survey designed to capture comprehensive, ...
Changes to Maintenance of Certification: New Pathways for Assessment
As you know, for more than 2 years, ASCO has been working closely with the American Board of Internal Medicine (ABIM) to shape the future of maintenance of certification (MOC) and assessment for our specialty. The ASCO MOC Task Force was charged by ASCO’s membership to make the process for...
Prostate Cancer Therapy in Evolution: Time to Rethink and Redirect?
The ASCO updated guidelines on the treatment of metastatic non-castrate prostate cancer penned by Morris and his colleagues1 provide valuable information annotated to the strengths of evidence in recently reported prostate cancer studies. CHAARTED, GETUG-AFU 15, LATITUDE, and STAMPEDE have...
De Novo Metastatic Prostate Cancer: Positive Recent News, Many Open Questions
After about 70 years with no significant progress, the landscape for men with de novo metastatic prostate cancer has changed dramatically in the past 4 years, with statistically significant and highly clinically meaningful survival improvement reported from multiple phase III trials when...
DNA Test Identifies Men With Sixfold Increased Risk of Prostate Cancer
A major new study of more than 140,000 men has identified 63 new genetic variations in the DNA code that increase the risk of prostate cancer. These findings were published by Schumacher et al in Nature Genetics. Researchers devised a new test combining these single-letter genetic variants with...
Parents See Cancer Prevention Potential as Best Reason for HPV Vaccination
Parents of adolescents believed that the potential to prevent certain types of cancer is the best reason for their children to receive the human papillomavirus (HPV) vaccine, whereas other reasons health-care providers often give were far less persuasive. Findings from this study were published by...
Journal of Oncology Practice Launches New Blog to Facilitate Discussions on Care Delivery Topics
The Journal of Oncology Practice (JOP) has launched a new care delivery blog, JOP DAiS (Discussion & Analysis in Short), to serve as a forum for commentary and analysis on issues affecting the mechanisms of oncology care delivery. This new platform will be a way to collaborate, debate, and...
ASCO/CAP Clinical Practice Guideline Focused Update on HER2 Testing in Breast Cancer
As reported in the Journal of Clinical Oncology by Antonio C. Wolff, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and colleagues, ASCO and the College of American Pathologists (CAP) have issued a clinical practice guideline focused update on HER2 testing in breast cancer....
Activity of Ivosidenib in IDH1-Mutated Relapsed or Refractory Acute Myeloid Leukemia
As reported at the 2018 ASCO Annual Meeting and in The New England Journal of Medicine by DiNardo et al, early-phase testing has shown activity of ivosidenib, an oral small-molecule inhibitor of mutant IDH1, in patients with IDH1-mutated relapsed or refractory acute myeloid leukemia (AML). IDH1...
ASCO Clinical Practice Guideline: Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer
As reported in the Journal of Clinical Oncology by Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, and colleagues, ASCO has released a clinical practice guideline on optimizing anticancer therapy in men with metastatic non-castrate prostate cancer.1 To ...
Expert Point of View: Naiyer Rizvi, MD
“In CheckMate 227, the benefit of nivolumab [Opdivo] plus ipilimumab [Yervoy] was the same in tumor mutational burden–high patients whether or not they were programmed cell death ligand 1 (PD-L1)–high or –low,” said formal discussant of this paper, Naiyer Rizvi, MD, Director of Thoracic Oncology...
Nivolumab Plus Ipilimumab Improves Progression-Free Survival in NSCLC With High Tumor Mutational Burden
The combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved progression-free survival compared with chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) and a high tumor mutational burden irrespective of programmed cell death ligand 1...
11 New Institutions Join AACR Project GENIE Consortium
The number of institutions participating in the American Association for Cancer Research (AACR) initiative, AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE), has increased by 11 participants. The 11 new institutions of the AACR Project GENIE consortium and their related cancer...
Optimizing Biologics in Metastatic Colon Cancer
Biologics are credited with increasing median overall survival in colorectal cancer to approximately 30 months. Their optimal use was discussed by Axel Grothey, MD, Professor of Oncology at the Mayo Clinic, Rochester, Minnesota, in an article he coauthored for the Journal of Oncology Practice 1...
Expert Point of View: Amir Fathi, MD, and Eunice S. Wang, MD
Commenting on this study, Amir Fathi, MD, a hematologist/oncologist at Massachusetts General Hospital and a co-investigator on the study, expressed hope about this new targeted approach. “Ivosidenib is an oral targeted inhibitor of the altered isocitrate dehydrogenase-1 (IDH1) protein. This...
Phase I Study Shows Safety, Efficacy of Ivosidenib in Acute Myeloid Leukemia
Ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, yielded durable and molecular remissions in some patients with IDH1-mutated advanced relapsed or refractory acute myeloid leukemia (AML). At a dose of 500 mg/d, ivosidenib was associated with a low frequency of grade 3 or higher...
Esomeprazole With Aspirin in Patients With Barrett’s Esophagus
An updated analysis of a randomized phase III trial showed that taking a high dose of esomeprazole with low-dose aspirin for at least 7 years may moderately reduce the risk of developing high-grade dysplasia or esophageal cancer and may delay death from any cause in people with Barrett’s esophagus. ...
Richard J. Bleicher, MD, FACS, Appointed Vice Chair of SSO’s Breast Fellowship Program Directors Committee
Richard J. Bleicher, MD, FACS, Professor of Surgical Oncology at Fox Chase Cancer Center, has been appointed Vice Chair of the Breast Fellowship Program Directors Committee of the Society of Surgical Oncology (SSO). In his new leadership role within SSO, Dr. Bleicher will be involved in the breast ...
Expert Point of View: Richard L. Schilsky, MD
“This study shows us that it is possible to get equally good outcomes with lower costs. In the United States, we have no real way to constrain the costs of health care, including the cost of drugs. The U.S. Food and Drug Administration does not consider drug price in deliberations about bringing...
Care for Colorectal Cancer Costs Twice as Much in Western Washington vs British Columbia, With Similar Survival
It is widely acknowledged that the costs of cancer care are much higher in the United States than in Canada, with outcomes that are thought to be similar. A new study presented at the 2018 ASCO Annual Meeting supports that view, by documenting and quantifying the differences in health-care costs...
